The Pediatric HIV AIDS Cohort Study addresses two critical research questions: (1) the consequences of fetal and infant exposure to antiretroviral therapy (ART) when used to prevent mother-to-child transmission of HIV-1, and (2) the clinical course of perinatal HIV infection among children as they proceed through adolescence towards adulthood. These questions are being addressed through two separate protocols being conducted at multiple sites in the US and Puerto Rico.
The specific aim of the SMARTT Study is, among HIV-exposed infants, to define the short and long-term safety of ART exposure. To accomplish this, HIV-uninfected children born to infected mothers are evaluated prospectively for growth, neurodevelopment, cardiac and other end-organ function. Children with abnormalities will be further evaluated to determine if they result from ART toxicity, with particular emphasis on mitochondrial dysfunction.
The specific aims of AMP are, among a cohort of pre-adolescents and adolescents with perinatal HIV (1) to define the impact of HIV infection and ART on: growth and development;sexual maturation;pubertal development;development of risk factors for cardiovascular disease;cognitive, academic, vocational, sexual, and social functioning;mental health;and risk taking behavior including substance use. (2) to identify infectious and non-infectious complication of HIV disease and ART therapy, including end organ disease (neurologic, renal, pulmonary, bone) and nutritional and metabolic abnormalities. (3) to study genetic, epigenetic, virologic (including antiretroviral resistance), and immunologic factors which impact the course of HIV infection, its complications and response to treatment. In both protocols, subjects and their primary caregivers are prospectively evaluated according to a standardized protocol. Both utilize a strategy of triggered evaluations, with specific abnormal findings leading to additional evaluations to characterize the abnormality. Repository specimens are collected for further biochemical and genetic testing.

Public Health Relevance

Defining the safety of preventive ART during pregnancy - including the safety of individual drugs - is necessary to define the safest strategy to prevent mother-to-transmission of HIV. Perinatal HIV has become a chronic condition, and an understanding of the long-term outcomes of the infection and its treatment is necessary to provide care for these children.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZHD1-DSR-A (06))
Program Officer
Mofenson, Lynne M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Tulane University
Schools of Medicine
New Orleans
United States
Zip Code
Williams, Paige L; Crain, Marilyn J; Yildirim, Cenk et al. (2015) Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr 169:48-55
Siberry, George K; Patel, Kunjal; Pinto, Jorge A et al. (2014) Elevated aspartate aminotransferase-to-platelet ratio index in perinatally HIV-infected children in the United States. Pediatr Infect Dis J 33:855-7
Garvie, Patricia A; Zeldow, Bret; Malee, Kathleen et al. (2014) Discordance of cognitive and academic achievement outcomes in youth with perinatal HIV exposure. Pediatr Infect Dis J 33:e232-8
Patel, Kunjal; Wang, Jiajia; Jacobson, Denise L et al. (2014) Aggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virus. Circulation 129:1204-12
Nozyce, Molly L; Huo, Yanling; Williams, Paige L et al. (2014) Safety of in utero and neonatal antiretroviral exposure: cognitive and academic outcomes in HIV-exposed, uninfected children 5-13 years of age. Pediatr Infect Dis J 33:1128-33
Alperen, Julie; Brummel, Sean; Tassiopoulos, Katherine et al. (2014) Prevalence of and risk factors for substance use among perinatally human immunodeficiency virus-infected and perinatally exposed but uninfected youth. J Adolesc Health 54:341-9
Persaud, Deborah; Patel, Kunjal; Karalius, Brad et al. (2014) Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. JAMA Pediatr 168:1138-46
Kapetanovic, Suad; Griner, Ray; Zeldow, Bret et al. (2014) Biomarkers and neurodevelopment in perinatally HIV-infected or exposed youth: a structural equation model analysis. AIDS 28:355-64
Lipshultz, Steven E; Chandar, Jayanthi J; Rusconi, Paolo G et al. (2014) Issues in solid-organ transplantation in children: translational research from bench to bedside. Clinics (Sao Paulo) 69 Suppl 1:55-72
Usitalo, Ann; Leister, Erin; Tassiopoulos, Katherine et al. (2014) Relationship between viral load and self-report measures of medication adherence among youth with perinatal HIV infection. AIDS Care 26:107-15

Showing the most recent 10 out of 46 publications